Publications by authors named "R de Vrueh"
Public-Private Partnerships (PPPs) have been crucial in medicine research and development (R&D) for decades. Initially, PPPs involved private and academic innovators working in bilateral collaborations to advance pharmaceutical innovation. Later, a precompetitive open innovation environment was created, where multiple public and private innovators collaborated on mutual interests.
View Article and Find Full Text PDFUNITE4TB: a new consortium for clinical drug and regimen development for TB.
Int J Tuberc Lung Dis
November 2021
Article Synopsis
- Schistosomiasis is a major public health issue, particularly in sub-Saharan Africa, with the World Health Organization aiming for its elimination by 2030 as part of the Neglected Tropical Diseases Roadmap.
- Current diagnostic methods like the Kato-Katz technique struggle to detect light-intensity infections, prompting the need for better tests; the point-of-care circulating cathodic antigen (POC-CCA) test has improved sensitivity but still faces challenges.
- This study found that antibody detection using recombinant protein antigens SmSerpin and RP26 can effectively identify light-intensity S. mansoni infections, showing a sensitivity of 83.7% and improved specificity compared to traditional methods.
Public Private Partnerships (PPPs) are multiple stakeholder partnerships designed to improve research efficacy. We focus on PPPs in the biomedical/pharmaceutical field, which emerged as a logical result of the open innovation model. Originally, a typical PPP was based on an academic and an industrial pillar, with governmental or other third party funding as an incentive.
View Article and Find Full Text PDF